Latest and Emerging Trends In Bioburden Testing Market 2019
ID: 1742153
The bioburden testing market is projected to reach USD 1,103 million by 2023 from USD 614 million in 2018, at a CAGR of 12.4%
(firmenpresse) - The bioburden testing market is projected to reach USD 1,103 million by 2023 from USD 614 million in 2018, at a CAGR of 12.4% during the forecast period. Factors such as growth in the medical devices, pharmaceutical, and biotechnology industries; rising safety concerns related to food and beverage products; and the increasing number of product recalls due to microbial contamination are expected to drive the growth of this market during the forecast period. However, the high cost of enumeration instruments is expected to restrain market growth in the coming years.
Based on product, the bioburden testing market is segmented into consumables and instruments. In 2018, the consumables segment is expected to account for the largest share of the global bioburden testing market. This segment is also projected to register the highest CAGR during the forecast period. The long shelf life and the recurrent purchase of media, kits, and reagents are driving the adoption of bioburden testing consumables.
On the basis of region, the market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest market share in 2018, and this trend is expected to continue during the forecast period. The large size of the North American biotechnology industry will aid the growth of the bioburden testing market in this region. However, the Asian market is expected to witness the highest growth during the forecast period. Strong investments and rapid growth in the pharmaceutical and biotechnology industries will drive the growth of the bioburden testing market in this region.
Pharmaceutical and biotechnology companies are the major end users of the bioburden testing market. In the pharmaceutical industry, bioburden testing is required at the quality control stage for raw materials, drugs, and other resources which are used in the manufacturing process. In the pharmaceutical manufacturing industry, bioburden testing is required to obtain regulatory approvals for products.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=17983056
Players in the bioburden testing market are adopting organic and inorganic growth strategies to further strengthen their presence and expand their product portfolios in the market. Some notable developments in this regard have been mentioned below:
In 2018, WuXi AppTec opened a Medical Device Testing center in China.
In 2018, Charles River acquired MPI Research, a premier nonclinical contract research organization (CRO).
In 2016, SGS acquired Quality Compliance Laboratories to provide microbiological and analytical testing services to pharmaceutical, nutraceutical, and cosmeceutical industries.
Weitere Infos zu dieser Pressemeldung:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Datum: 02.08.2019 - 10:04 Uhr
Sprache: Deutsch
News-ID 1742153
Anzahl Zeichen: 2975
Kontakt-Informationen:
Ansprechpartner: Dheeraj Shaha
Stadt:
Northbrook
Telefon: 18886006441
Kategorie:
Biotechnologie
Meldungsart: Finanzinformation
Versandart: Veröffentlichung
Freigabedatum: 02.08.2019
Anmerkungen:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Diese Pressemitteilung wurde bisher 490 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Latest and Emerging Trends In Bioburden Testing Market 2019"
steht unter der journalistisch-redaktionellen Verantwortung von
MnM (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
The growth of this market is mainly driven by factors such as the increasing R&D expenditure in the pharmaceutical industry, increasing focus on miniaturization, technological advancements, and growing prevalence of diseases. The report "Microplate Systems Market by Product (Microplate R
3D Cell Culture Market : Regenerative Medicine to Offer Global Growth In Coming Years ...
A 3D cell culture is an artificially created environment in which biological cells are permitted to grow or interact with their surroundings in all three dimensions. Factors such as rising focus on developing alternative methods for animal testing, funding initiatives from government and private
Immuno Oncology Assays : Research Application Transforming the Industrial Business ...
What the Immuno Oncology Assays Market looks like? Growth in Immuno Oncology Assays Market is largely driven by factors such as the increasing adoption of targeted therapy over traditional therapy and the increasing demand for mAbs. According to the new market research report "Immuno Onco
Weitere Mitteilungen von MnM
Forscher revolutionieren 3D-Bioprinting mit biotechnologisch erstellten funktionellen Komponenten des menschlichen Herzens ...
Ein Forscherteam der Carnegie Mellon University hat ein Papier in Science veröffentlicht, das eine neue Technik beschreibt, die es allgemein möglich macht, über 3D-Druck Gewebegerüste aus Kollagen zu erstellen, dem wichtigsten Strukturprotein im menschlichen Körper. Dieses vollständig neue
Fujifilm schließ die Übernahme des Biogen-Produktionsstandorts in Dänemark ab ...
Die FUJIFILM Corporation ("Fujifilm") gab heute bekannt, dass sie die Übernahme eines großen Produktionsstandorts für Biologika namens Biogen (Denmark) Manufacturing ApS in Hillerød in der Nähe von Kopenhagen, Dänemark ("Hillerød Manufacturing") von Biogen abgeschlossen
Pöppelmann TEKU® ...
Pöppelmann TEKU® präsentiert sich auf der Green is life 2019, Internationale Fachmesse für Pflanzen, Gartentechnik und Landschaftsbau in Warschau/Polen, mit einem breiten Sortiment an innovativen Lösungen für den Erwerbsgartenbau. Der Kunststoffspezialist zeigt komplett recycelbare Pflanztöpf
GEMoaB gibt erstmalige klinische Behandlung mit dem 'Affinity-Tailored T-Cell Adaptor' (ATAC) GEM3PSCA in einer Phase-I-Studie bei fortgeschrittenen PSCA-positiven soliden Tumoren bekannt ...
GEMoaB GmbH, ein biopharmazeutisches Unternehmen, das sich auf die Entdeckung, Entwicklung, Herstellung und Vermarktung von Immuntherapien der nächsten Generation für schwer behandelbare Krebserkrankungen spezialisiert hat, gab heute die erstmalige klinische Behandlung mit dem 'Affinity-
